Alisa Lask Joins CollPlant’s Board of Directors

Industry vet Alisa Lask is now a member of CollPlant’s Board of Directors. 

Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlant Board. CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

"Alisa brings a strong background in global strategy and marketing that will be very helpful to maximizing the value of co-developments with industry leaders in medical aesthetics and 3D bioprinting," says Yehiel Tal, CEO of CollPlant, in a news release. "Alisa is an excellent addition to our Board. She has valuable insights and a diverse skill set that will play an integral role in our mission to help people live longer and better with products developed through our plant-based collagen technology platform."

"CollPlant has been rapidly expanding its commercial partnerships with global leaders and I am delighted to join the Board of Directors during this exciting time. I look forward to contributing to CollPlant's future growth and success as the company continues to innovate in the field of regenerative medicine, especially relating to aesthetics," adds Ms. Lask.  

"CollPlant is committed to adding Board members with a track record of accomplishment and a strong strategic vision," says CollPlant Chairman Dr. Roger J. Pomerantz. "We welcome Alisa Lask at this important stage of the Company's growth to help leverage our strong R&D capabilities and external collaborations to develop innovative regenerative medicine products."

Ms. Lask is the former Vice President and General Manager of US Aesthetics at Galderma.  Previously, she was a Senior Director of Global Strategic Marketing of Facial Aesthetics at Allergan. Earlier, she held strategic marketing positions at both Zimmer Biomet and Eli Lilly. Ms. Lask received an M.B.A  from the University of Michigan and has a B.A. in marketing from Miami University, Oxford, Ohio.  

CollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.